KOD$26.6
Chart
Performance
Key Stats
AI KOD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyKodiak Sciences Inc. (KOD) exhibits strong long-term potential driven by its focus on retinal diseases and promising clinical pipeline. However, current financial performance indicates significant cash burn, and the valuation, while improved, still reflects future growth expectations. Technical indicators show a recent bullish trend but also signs of overextension.
Thematic
Kodiak Sciences operates in the growing biopharmaceutical sector with a specific focus on ophthalmology, a market driven by an aging global population and advancements in treatment. The company's specialization in retinal diseases positions it to address significant unmet medical needs.
Fundamental
Kodiak Sciences has zero revenue and a significant net loss, characteristic of a clinical-stage biopharmaceutical company. While its cash position is adequate for its current stage, its long-term viability depends on successful product commercialization and financing. Valuation metrics are not traditionally applicable due to lack of revenue and earnings.
Technical
KOD has experienced significant price appreciation over the past year. Current technical indicators suggest a strong upward momentum but also show signs of being in overbought territory on shorter timeframes, indicating a potential for consolidation or a brief pullback before further upward movement.
| Factor | Score |
|---|---|
| Aging Population | 85 |
| Biopharmaceutical Innovation | 75 |
| Competition | 60 |
| Regulatory Landscape | 65 |
| Factor | Score |
|---|---|
| Revenue | 0 |
| Profitability | 5 |
| Earnings Per Share (EPS) | 5 |
| Balance Sheet Health | 60 |
| Debt Level | 70 |
| Cash Flow | 20 |
| Valuation | 30 |
| Factor | Score |
|---|---|
| Price Trend | 80 |
| Moving Averages | 85 |
| Momentum Indicators | 50 |
| Volatility | 40 |
| Support/Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Significant Positive Price Movement
The stock price has seen a notable increase of 1.52% today, reaching $8.375. Over the past 1-month period, the stock has delivered an impressive 126.35% return, and a strong 179.17% return over the past year, indicating robust recent performance.
Broadly Bullish Moving Averages
Multiple Exponential and Simple Moving Averages (10, 20, 30, 50, 100, 200 day) are indicating a 'Buy' action, suggesting a sustained upward trend across various timeframes.
Bearish Points (7)
Consistent Negative Earnings
The company has consistently reported negative Earnings Per Share (EPS) on a trailing twelve months (TTM) basis (-$3.62) and for all reported quarters, indicating it is not yet profitable.
Lack of Meaningful Revenue and Profitability Metrics
The reported revenue for recent periods is $0, and the Price-to-Sales (P/S) ratio is reported as 0.0. The Price-to-Earnings (P/E) ratio is negative (-3.0 TTM), making traditional valuation metrics unusable and highlighting the speculative nature of the investment.
Calendar
August 2025
12
Next Earnings Date
H: $-0.95
A: $-1.05
L: $-1.16
Profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Seasonals
Price Target
7.25 USD
The 39 analysts offering 1 year price forecasts for KOD have a max estimate of 20.00 and a min estimate of 2.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor in the oral Hereditary Angioedema (HAE) treatment market with Orladeyo, similar to KalVista's Sebetralstat.
Weight: 90
Major player in the Hereditary Angioedema (HAE) market with leading products like Takhzyro and Firazyr.
Weight: 90
Global leader in plasma-derived therapies, including significant HAE treatments such as Haegarda and Berinert.
Weight: 88
Commercialized HAE treatment (Ruconest), making it a direct competitor in the Hereditary Angioedema market.